Why did 4506.T stock fall sharply on 20 Jan 2026?

The drop to **JPY 2,255.50** reflected heavy volume, profit-taking after a strong 1-year rally, and broader Nikkei weakness. Market coverage highlighted the stock among session losers and traders are positioning ahead of the company’s earnings on 30 Jan 2026.

Is 4506.T stock cheap based on fundamentals?

On EPS and trailing PE (**6.13**) Sumitomo Pharma looks inexpensive, but PB (**3.57**) and elevated leverage (debt/equity **0.99**) temper that view. Valuation must be weighed against sector peers and pipeline risk.

What is Meyka AI's short-term forecast for 4506.T stock?

Meyka AI's forecast model projects a monthly target of **JPY 3,157.81**, implying roughly **40.02%** upside versus the current **JPY 2,255.50**. Models are projections and not guarantees.

How should traders manage risk after the 4506.T stock drop?

Given higher ATR and overbought-to-volatile conditions, use tight position sizing, set stop-loss near **JPY 2,100.00** for short-term longs, and avoid levering before the 30 Jan 2026 earnings release.

JP Stocks

4506.T stock -17.98% to JPY 2255.50 at JPX close 20 Jan 2026: next steps

ByDanny Kontos January 20, 2026

The selloff in Sumitomo Pharma Co., Ltd. (4506.T) ended the JPX session at JPY 2,255.50, down 17.98% on 20 Jan 2026 as volume surged to 12,033,300 shares. 4506.T stock led the losers on the Nikkei after profit-taking and headline weakness pushed price below yesterday’s close of JPY 2,750.00. Traders face a near-term catalyst with the company’s earnings announcement scheduled for 30 Jan 2026, making this drop a key inflection for short-term positions and longer-term valuation debates.